Yahoo
NYSE - Nasdaq Real Time Price USD

Oscar Health, Inc. (OSCR)

28.40 +0.13 (+0.46%)
At close: June 18 at 4:00:03 PM EDT
Trade OSCR on Coinbase
Chart Range Bar
Loading chart for OSCR
  • Previous Close 28.27
  • Open 28.57
  • Bid 28.10 x 90000
  • Ask 28.12 x 20000
  • Day's Range 27.57 - 28.85
  • 52 Week Range 10.69 - 29.81
  • Volume 4,815,925
  • Avg. Volume 7,505,061
  • Market Cap (intraday) 8.562B
  • Beta (5Y Monthly) 2.39
  • PE Ratio (TTM) --
  • EPS (TTM) -0.54
  • Earnings Date May 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.60

Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

www.hioscar.com

2,305

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Healthcare Plans

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OSCR
97.63%
S&P 500 (^GSPC)
9.57%

1-Year Return

OSCR
51.31%
S&P 500 (^GSPC)
25.41%

3-Year Return

OSCR
220.90%
S&P 500 (^GSPC)
70.10%

5-Year Return

OSCR
19.03%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 4.65B
Earnings 679M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1B
2B
3B
4B

Analyst Insights

View More

Analyst Price Targets

13.00 Low
22.60 Average
28.40 Current
35.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/10/2026
Analyst Barclays
Rating Action Upgrade
Rating Overweight
Price Action Raises
Price Target 30 -> 35

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    8.56B

  • Enterprise Value

    4.19B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.59

  • Price/Book (mrq)

    5.15

  • Enterprise Value/Revenue

    0.31

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.30%

  • Return on Assets (ttm)

    0.09%

  • Return on Equity (ttm)

    -2.62%

  • Revenue (ttm)

    13.3B

  • Net Income Avi to Common (ttm)

    -39.43M

  • Diluted EPS (ttm)

    -0.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.8B

  • Total Debt/Equity (mrq)

    28.93%

  • Levered Free Cash Flow (ttm)

    1.63B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

28.40 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: